XML 67 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)
 12 Months Ended
Dec. 31, 2023
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Results and Market for Company's Stock The results of operations of any quarter are not necessarily indicative of the results that may be expected for any future period.
2023
(in millions, except per share data)First
Quarter
Second Quarter2
Third
Quarter3
Fourth Quarter
Full Year 1
Net sales$3,513 $3,707 $3,708 $3,885 $14,813 
Gross margin1,275 1,111 1,117 1,472 4,975 
Income (loss) from continuing operations— (193)51 73 (69)
Income (loss) from discontinued operations45 54 2,460 173 2,732 
Net income (loss)45 (139)2,511 246 2,663 
Net income (loss) attributable to Baxter stockholders44 (141)2,508 245 2,656 
Income (loss) from continuing operations per common share
Basic$0.00 $(0.39)$0.09 $0.14 $(0.15)
Diluted$0.00 $(0.39)$0.09 $0.14 $(0.15)
Income (loss) from discontinued operations per common share
Basic$0.09 $0.11 $4.85 $0.34 $5.40 
Diluted$0.09 $0.11 $4.83 $0.34 $5.40 
Net Income (loss) per common share
Basic$0.09 $(0.28)$4.95 $0.48 $5.25 
Diluted$0.09 $(0.28)$4.93 $0.48 $5.25 

2022
(in millions, except per share data)First
Quarter		Second Quarter
Third
Quarter4
Fourth Quarter
Full Year 1
Net sales$3,558 $3,594 $3,609 $3,745 $14,506 
Gross margin1,262 1,371 1,045 1,388 5,066 
Income (loss) from continuing operations8 185 (2,991)144 (2,654)
Income from discontinued operations65 70 57 41 233 
Net income (loss)73 255 (2,934)185 (2,421)
Net income (loss) attributable to Baxter stockholders71 252 (2,937)181 (2,433)
Income (loss) from continuing operations per common share
Basic$0.01 $0.36 $(5.94)$0.28 $(5.29)
Diluted$0.01 $0.36 $(5.94)$0.28 $(5.29)
Income from discontinued operations per common share
Basic$0.13 $0.14 $0.11 $0.08 $0.46 
Diluted$0.13 $0.14 $0.11 $0.08 $0.46 
Net Income (loss) per common share
Basic$0.14 $0.50 $(5.83)$0.36 $(4.83)
Diluted$0.14 $0.50 $(5.83)$0.36 $(4.83)
1The sum of per share amounts for quarterly periods may not equal full year amounts due to rounding.
2Our results from continuing operations for the quarter ended June 30, 2023 included $243 million of long-lived asset impairment charges resulting from our decision to cease production at one of our dialyzer manufacturing facilities.
3Our results from continuing operations for the quarter ended September 30, 2023 included $267 million of long-lived asset impairment charges related to our HD business and our results from discontinued operations for that quarterly period included a gain of $2.88 billion from the sale of our BPS business.
4Our results from continuing operations for the quarter ended September 30, 2022 included $2.79 billion of goodwill impairments and $332 million of long-lived asset impairments related to assets acquired in connection with our December 2021 acquisition of Hillrom.